These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 6797689)

  • 1. [Inhibitory effect of arginine butyrate on the development of Crocker 180/TG tumor in Swiss mice].
    Chany C; Cerutti I
    C R Seances Acad Sci III; 1981 Oct; 293(7):367-9. PubMed ID: 6797689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor effect of arginine butyrate in conjunction with Corynebacterium parvum and interferon.
    Chany C; Cerutti I
    Int J Cancer; 1982 Oct; 30(4):489-93. PubMed ID: 6183228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of coordinated therapeutic assays using C. parvum, interferon and arginine butyrate on spontaneous disease and survival of AKR mice.
    Chany C; Cerutti I; Mace B
    Int J Cancer; 1983 Sep; 32(3):379-83. PubMed ID: 6193071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Studies on antitumor effect of corynebacterium parvum and pustulan on Lewis lung carcinoma in mice.
    Budzyński W
    Arch Immunol Ther Exp (Warsz); 1982; 30(5-6):379-84. PubMed ID: 7184489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proceedings: Immunotherapy of Moloney sarcoma virus tumours in mice with Corynebacterium parvum.
    Hamilton DN; Bell PR
    Br J Surg; 1974 Apr; 61(4):321. PubMed ID: 4832648
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of vaccine prepared from Corynebacterium parvum on the growth of Gardner lymphosarcoma in C3H strain mice.
    Motycka K; Chudomel V; Bednár M; Bostík J
    Arch Immunol Ther Exp (Warsz); 1984; 32(4):405-12. PubMed ID: 6549499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor therapy based on the use of an immune modulator, arginine butyrate and interferon.
    Chany C; Cerutti I
    Med Oncol Tumor Pharmacother; 1984; 1(2):101-7. PubMed ID: 6085812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancement of interferon antitumor action by sodium butyrate.
    Bourgeade MF; Cerutti I; Chany C
    Cancer Res; 1979 Nov; 39(11):4720-3. PubMed ID: 498098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of C3H mice bearing solid Gardner lymphosarcoma with vaccine prepared from Corynebacterium parvum combined with methotrexate and Alexan.
    Motycka K; Chudomel V; Bednár M; Bostík J
    Arch Immunol Ther Exp (Warsz); 1984; 32(4):413-9. PubMed ID: 6549500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumour growth, phagocytic activity and antibody response in Corynebacterium parvum-treated mice.
    Woodruff MF; McBride WH; Dunbar N
    Clin Exp Immunol; 1974 Jul; 17(3):509-18. PubMed ID: 4549691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal conditions for antitumor activity of C. parvum against the ascites form of sarcoma 180.
    Megirian R; Astry CL; Spoor RP; Loose LD
    J Immunopharmacol; 1980; 2(1):99-112. PubMed ID: 7452006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of arginine butyrate and tributyrylxylitol on cultured human sarcoma cells.
    Vincent-Fiquet O; Rogez JC; Boitte F; Brazier M; Desmet G
    Anticancer Res; 1994; 14(5A):1823-8. PubMed ID: 7531414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Immunotherapy with Corynebacterium parvum in experimental influenza virus infections and mixed infections in mice].
    Denys A; Kowalska M; Szydłowska T; Białek J
    Pol Tyg Lek; 1986 May; 41(19):619-23. PubMed ID: 3763446
    [No Abstract]   [Full Text] [Related]  

  • 14. Antiviral effects of Corynebacterium parvum and its effect on the interferon system in mice.
    Kirchner H; Chmielarczyk W; Storch E; Schindler L
    Behring Inst Mitt; 1984 May; (74):183-8. PubMed ID: 6206840
    [No Abstract]   [Full Text] [Related]  

  • 15. Antitumor activity of Corynebacterium parvum and retinyl palmitate used in combination on the Lewis lung carcinoma.
    Pavelic ZP; Dave S; Bialkowski S; Priore RL; Greco WR
    Cancer Res; 1980 Dec; 40(12):4617-21. PubMed ID: 7438095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effects on the lymphreticular system and inhibition of liver microsomaal cytochrome P-450 in mice administered Priopionibacterium acnes (Corynebacterium parvum) bacterin].
    Ocenásková J; Mára M; Bednár M; Veselská M; Adamcová D
    Cesk Epidemiol Mikrobiol Imunol; 1985 Mar; 34(2):100-6. PubMed ID: 3157461
    [No Abstract]   [Full Text] [Related]  

  • 17. Inefficacy of sc Corynebacterium parvum in stage I malignant melanoma: preliminary results of a single-institution pilot study.
    Murray JL; Ishmael DR; Bottomley RH; Grozea PN; Lee ET
    Cancer Treat Rep; 1983 Feb; 67(2):191-2. PubMed ID: 6825130
    [No Abstract]   [Full Text] [Related]  

  • 18. Effect of immunomodulation on the fate of tumor cells in the central nervous system and systemic organs of mice. Distribution of [125I]5-Iodo-2'-deoxyuridine-labeled KHT tumor cells after left intracardial injection.
    Conley FK
    J Natl Cancer Inst; 1982 Aug; 69(2):465-73. PubMed ID: 6955547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of the "Corynebacterium parvum" vaccine and stilbostat on intratesticular development of Walker 256 carcinosarcoma in hyper- or hypothyroidized Wistar rats.
    Zimel A; Taşcă C; Ghinea E; Stefäneanu L
    Endocrinologie; 1981; 19(2):105-10. PubMed ID: 7256164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of Corynebacterium parvum on T cell dependent tumor regression.
    McBride WH; Peters LJ; Mason KA; Barrow G
    J Reticuloendothel Soc; 1980 Feb; 27(2):151-8. PubMed ID: 6965725
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.